PMS60 Biologic Discontinuation In Rheumatoid Arthritis: Experience From Canadian Clinics  by Choquette, D. et al.
 VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 1 – A 3 0 7  A163
Muscular-skeletal DisorDers – Patient-reported outcomes & Patient 
Preference studies
PMs60
Biologic Discontinuation in rheuMatoiD arthritis: exPerience FroM 
canaDian clinics
Choquette D.1, Coupal L.1, Laliberté M.2, Desjardins O.2
1Institut de Rhumatologie de Montréal, Montreal, QC, Canada, 2AbbVie, Saint-Laurent, QC, 
Canada
OBJECTIVES: The purpose of this study was to describe biologic discontinuation 
and assess the predictors of discontinuation in Canadian rheumatoid arthritis (RA) 
patients. METHODS: In this prospective cohort study, adult patients included in the 
RHUMADATA database with a diagnosis of RA and treated with at least one biologic 
since 2003 were selected. The RHUMADATA database includes clinical, laboratory 
and socioeconomic information of patients with rheumatic diseases followed in 
three Canadian rheumatology centers (Montreal, Quebec and Rimouski). Patients 
were followed for three years after therapy initiation or until treatment discontinu-
ation, as measured using pharmacy records. Time to discontinuation and predic-
tors of treatment discontinuation were explored using Cox proportional hazards 
models. RESULTS: A total of 623 eligible patients were treated with at least one 
biologic. The average age was 53.2 years (SD= 12.4), 77% were women and patients 
had been diagnosed for an average of 7.7 years. The average time on treatment for 
the first biologic agent was 1.7 years (SD= 2.1). In all, 233 (37%), 326 (52%), 405 (65%), 
and 438 (70%) patients had stopped their first biologic after 6, 12, 24, and 36 months, 
respectively. In time-to-event analyses (Cox proportional hazard models), type of 
work [part time vs. full time; hazard ratio (HR): 1.57; 95% confidence interval (CI): 
1.05-2.34] and income [$20,000 to $40,000 vs. less than $20,000 (HR: 1.35; 1.01-1.80) 
and $80,000 to $100,000 vs. less than $20,000 (HR: 2.16; 1.23-3.80)] were significantly 
associated with biologic discontinuation over the complete treatment duration. The 
number of disease-modifying antirheumatic drugs used (HR: 0.89; 0.80-0.99) and 
use of methotrexate (yes vs. no; HR: 0.80; 0.64-0.99) were associated with a reduced 
risk of biologic discontinuation. CONCLUSIONS: In this real-life Canadian study, 
high biologic discontinuation rates were observed. This study also suggests that 
many clinical and socioeconomic variables are predictors of biologic discontinu-
ation in RA patients.
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OBJECTIVES: Rheumatoid arthritis (RA) is a chronic inflammatory disorder that 
affects the lining of joints, causing painful swelling that can result in bone ero-
sion and joint deformity. Patient adherence to medications can help reduce or 
lessen inflammation; however, non-adherence and frequent switching are rec-
ognized problems in patients with RA. The objectives of this study are to bet-
ter understand patients’ reason(s) for being non-adherent and/or switching and 
physicians’ reasons for recommending a switch. METHODS: We extracted 300 
records for RA patients from a unique database of physician-patient interactions 
(RealHealthData). Using Atlas.ti, we analyzed these records to analyze trends for 
medication switches and/or non-adherence, i.e., when, why and how patients 
stopped or switched their medication. In addition, we analyzed physicians’ noted 
reasons for switching. RESULTS: On average, patients were 53 years old (±10). 
Patients’ functional disability was similar to the general RA population, with a 
noted variability of swelling and joint pain. The medications prescribed to the 
patients included: methotrexate (22%), Orencia (18%), Remicade (14%), Plaquenil 
(14%), Humira (13%) Enbrel (8%), Acterma (6%) and CellCept (5%). Patients’ reported 
reasons for switching and/or non-adherence included: increased pain/swelling 
(34%), feeling the medication is not working and/or continual progression of 
symptoms (35%) and adverse reaction to medication such as itching (11%) and 
GI complications (11%). Of the physicians who recommended switching, reasons 
for switching their patients’ medications included potential toxicities associated 
with drugs (46%) and observed disease progression (34%). CONCLUSIONS: It is 
critical to better understand patients’ and physicians’ reasons for switching medi-
cation for chronic disease like RA. The more we know about reasons for behavior, 
the more we can actively plan and organize research, development and outreach 
that is patient-centric and clinically meaningful. Our results demonstrate that 
using physician-patient interaction data can add tremendous value to outcomes 
researchers and healthcare decision makers.
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OBJECTIVES: To study the impact of rheumatoid arthritis on self-reported work 
productivity, disease severity and adherence in an employed population METHODS: 
A total of 1,041 patients with rheumatoid arthritis (RA) were identified from a list of 
3000 patients (18-65 years) from a Specialty Pharmacy database. Survey to the RA 
sample included the Work Productivity and Activity Impairment (WPAI) question-
naire, Health Assessment Questionnaire (HAQ) and Modified Morisky Scale (MMS). A 
demographic survey was also administered. Survey responses were linked to clinical 
measures obtained from the Specialty Pharmacy database. Univariate and multi-
variate regression analyses were conducted using SPSS version 22.0. RESULTS: The 
response rate was 30.45% (n= 317) and 57.4% (n= 174) reported as being employed. 
Mean age and disease duration of employed patients were 54.09+9.97 years and 
15.21+9.11 years, respectively. Employed patients were mostly female (66.5%), mar-
OBJECTIVES: Bisphosphonates are anti-osteoporosis medication. This study evalu-
ated the cost-effectiveness of the use of bisphosphonates in secondary prevention 
of hip fracture in a naturalistic setting from the payer perspective. METHODS: Using 
the 1997-2007 Taiwan’s National Health Insurance research database, we identified 
patients with the first-ever hospitalization experience for hip fracture between 
1998 and 2000. The patients who received bisphosphonates within the first year of 
hip fracture were grouped into “bisphosphonates cohort”; those who received no 
anti-osteoporosis medications were grouped into “untreated cohort”. The date of 
the hip fracture served as the date of cohort entry. The two cohorts were followed up 
for hip re-fracture and osteoporosis-related medical costs. A Cox regression model 
was used to compare the risk of hip re-fracture and a generalized linear model was 
used to compare the osteoporosis-related costs between the cohorts. RESULTS: 
Among 3,427 patients identified, 161 received bisphosphonates and 3,266 were 
left untreated. The mean follow-up period of the bisphosphonates cohort and the 
untreated cohort were 5.11 and 4.72 years. There was no significant difference in 
the risk of re-fracture between the two groups (adjusted hazard ratio = 1.24, 95% CI 
0.87-1.78, p= 0.227). However, the osteoporosis-related costs of the bisphosphonates 
cohort were significantly higher than the untreated cohort (the average incremen-
tal cost was 29,227 point values, 95% CI 14,890-43,564, p< 0.001). Further analysis 
showed that the use of bisphosphonates is likely to be cost-saving from a one-year 
perspective; the probability of cost-saving was 73.8%. CONCLUSIONS: This study 
found the use of bisphosphonates for the secondary prevention of hip fracture was 
cost-ineffective in a naturalistic setting.
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BACKGROUND: Rheumatoid arthritis (RA) is a common autoimmune disease associ-
ated with considerable morbidity rates and diminished quality of life. For patients 
who have an inadequate response to disease-modifying antirheumatic drugs 
(DMARDs), the use of biologic agents and JAK inhibitor has proved to be effective 
as second-line treatment. [1]. OBJECTIVES: To evaluate the cost-effectiveness of 
Tofacitinib as second line treatment vs using the standard biological therapies as 
second line treatments in patients with moderate RA after failure of DMARDs in 
Guatemala Health Care System (IGSS) in 2014. METHODS: A patient-level simula-
tion model was used to evaluate costs and health benefits. This cost-effectiveness 
model compares two sequences of treatments: one using Tofacitinib as second line 
treatment followed by biological therapies (Tofacitinib-Infliximab-Adalimumab-
Etanercept-Tocilizumab-Rituximab-salvage therapy ) and the other using the same 
biologic therapies scheme but excluding Tofacitinib; these schemes are defined 
according to experts opinion from IGSS [2]. All patients received concomitant treat-
ment with methotrexate. Model inputs are: age, weight, initial HAQ score, severe 
adverse events (SAE) and clinical response to short and long term treatment; rand-
omized controlled trials were used as a source information when local information 
was not available [3,4]. HAQ scores were used to calculate utilities, measured in 
QALYs [5,6,7]. Only direct costs were considered using institutional databases from 
2014. [8]. Annual discount rate was 5%, the time horizon is to lifetime. RESULTS: 
Total cost and total QALY per patient in a lifetime period are estimated to be $213,009 
and 8.83 QALY for the treatment sequence with Tofacitinib; $222,145 and 8.52 for 
treatment sequence with biologic therapy only. The cost savings from the treatment 
sequence with Tofacitinib are 15.2% in the first year, 15.0% in 5 year and 10.7% in 
ten years. CONCLUSIONS: For the IGSS, the sequence initiating with Tofacitinib is 
a cost-saving alternative compared with the standard biologic therapy
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OBJECTIVES: Osteoarthritis is the most common form of arthritis, affecting 27 mil-
lion individuals in the United States. This study assessed incremental workplace 
absenteeism associated with osteoarthritis over one year. METHODS: Data from 
the 2011 Medical Expenditure Panel Survey (MEPS) was used for analyses. Sample 
inclusion criteria were being employed and at least eighteen years old. Individuals 
suffering from osteoarthritis were identified based on International Classification 
of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) diagnosis code of 715 in 
claims. Exclusion criteria were missing information on any variable. A zero inflated 
negative binomial regression was used with annual days missed at work as the 
response variable and a binary variable indicating osteoarthritis as the primary 
predictor. Covariates in the model adjusted for age, sex, education, race, marital 
status, occupation, region, insurance, hypertension, diabetes, anxiety, asthma, 
degree, hyperlipidemia and Charlson Comorbidity Index score. To account for the 
complex survey sample, sampling weights were incorporated in the model. Analyses 
were carried out using STATA for UNIX version 12.1 with an a priori alpha level of 
0.05. RESULTS: Among 10,597 individuals in the sample, 386 individuals had osteo-
arthritis. One-half of the sample was 47 years or younger, 54.43% were females, and 
70% were Caucasians. The expected number of days absent for individuals with 
osteoarthritis was 1.36 times the expected number of days absent for individuals 
without osteoarthritis (p= 0.038). Incremental annual days missed at work was 2.08 
days for individuals with osteoarthritis as compared to individuals without osteoar-
thritis (p= 0.037). Among covariates that were significant, expected number of days 
absent for individuals with hypertension was 1.37 times the expected number of 
days absent for those without hypertension (p< 0.01). The expected number of days 
absent for females was 1.54 times the expected number of days absent for males 
(p< 0.001). CONCLUSIONS: Osteoarthritis diagnosis is associated with significant 
incremental work absenteeism.
